1. Home
  2. XXI vs MPLT Comparison

XXI vs MPLT Comparison

Compare XXI & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twenty One Capital Inc. Class A Common Stock

XXI

Twenty One Capital Inc. Class A Common Stock

N/A

Current Price

$4.58

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$10.09

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XXI
MPLT
Founded
2025
2018
Country
United States
United States
Employees
3
133
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XXI
MPLT
Price
$4.58
$10.09
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.67
AVG Volume (30 Days)
1.5M
509.6K
Earning Date
06-12-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.27
$12.24
52 Week High
$11.49
$40.43

Technical Indicators

Market Signals
Indicator
XXI
MPLT
Relative Strength Index (RSI) 34.88 21.32
Support Level N/A N/A
Resistance Level $5.71 $20.73
Average True Range (ATR) 0.30 2.77
MACD -0.03 -2.03
Stochastic Oscillator 27.92 0.79

Price Performance

Historical Comparison
XXI
MPLT

About XXI Twenty One Capital Inc. Class A Common Stock

Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: